The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Headline
The U.S. District Court for the District of Massachusetts yesterday ruled in favor of 25 states and the District of Columbia to vacate the Centers for Medicare…
Headline
Extending Medicaid coverage by 12 months following childbirth increased use of postpartum care among mothers with pregnancy complications such as diabetes and…
Headline
The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to…
Headline
The AHA has released its latest downloadable Fast Facts infographic providing statistics on the number of behavioral health hospitals and hospital services in…
Headline
In this conversation, Brent Davis, CEO of the primary health division at AdventHealth, shares how improved patient access, coordinated care teams, virtual care…
Headline
A new AHA report warns that access to care is increasingly at risk in rural communities as workforce shortages, financial pressures and policy changes threaten…